Britannia Pharmaceuticals Ltd.   Report issue

For profit Phase 3
Founded: Reading United Kingdom (1982)
Status: No NME R&D (1982)

Organization Overview

First Clinical Trial
2001
NCT00032942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

apomorphine (apokyn) (2 trials)

lofexidine (lucemyra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Opioid-Related Disorders (Phase 3)

Parkinson Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2